What is the difference between diane 35 and diane 35 ed

If vomiting occurs within hours after tablet-taking, the advice concerning missed tablets, as given in Management of missed tablets as previously mentioned, is applicable.

If the woman does not want to change her normal tablet-taking schedule, she has to take the extra tablet s needed from another pack. Length of use: The length of use depends on the severity of the symptoms of androgenization and their response to treatment. In general, treatment should be carried out over several months. Time to relieve of symptoms is at least three months. Acne and seborrhea usually respond sooner than hirsutism.

The need to continue treatment should be evaluated periodically by the treating physician. Geriatric patients: Not applicable. See also Contraindications. Available data do not suggest a change in treatment in this patient population.

There have been no reports of serious deleterious effects from overdose. Symptoms that may occur in this case are: nausea, vomiting and withdrawal bleeding.

The last may even occur in girls before their menarche, if they have accidentally taken the medicinal product. There are no antidotes and further treatment should be symptomatic. Should any of the conditions appear for the first time during their use, the product should be stopped immediately. Presence or a history of prodromi of a thrombosis e.

A high risk of venous or arterial thrombosis see Precautions. History of migraine with focal neurological symptoms. Diabetes mellitus with vascular involvement. Severe hepatic disease as long as liver function values have not returned to normal.

Use of direct-acting antiviral DAA medicinal products containing ombitasvir, paritaprevir, or dasabuvir, and combinations of these see Interactions. Presence or history of liver tumors benign or malignant.

Known or suspected sex-steroid influenced malignancies e. Undiagnosed vaginal bleeding. Known or suspected pregnancy. Hypersensitivity to the active substances or to any of the excipients.

Special Precautions. It has a similar composition to that of a combined oral contraceptive COC. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. Epidemiological studies have suggested an association between the use of COCs and an increased risk of arterial and venous thrombotic and thromboembolic diseases such as myocardial infarction, deep venous thrombosis, pulmonary embolism and of cerebrovascular accidents.

These events occur rarely. The risk of VTE is highest during the first year of use. This increased risk is present after initially starting a COC or restarting following a 4 week or greater pill free interval the same or a different COC. Data from a large, prospective 3-armed cohort study suggest that this increased risk is mainly present during the first 3 months.

Extremely rarely, thrombosis has been reported to occur in other blood vessels, e. Symptoms of deep venous thrombosis DVT can include: unilateral swelling of the leg or along a vein in the leg; pain or tenderness in the leg which may be felt only when standing or walking, increased warmth in the affected leg; red or discolored skin on the leg. Symptoms of pulmonary embolism PE can include: sudden onset of unexplained shortness of breath or rapid breathing; sudden coughing which may bring up blood; sharp chest pain which may increase with deep breathing; sense of anxiety; severe light headedness or dizziness; rapid or irregular heartbeat.

Some of these symptoms e. An arterial thromboembolic event can include cerebrovascular accident, vascular occlusion or myocardial infarction MI. Symptoms of a cerebrovascular accident can include: sudden numbness or weakness of the face, arm or leg, especially on one side of the body; sudden confusion, trouble speaking or understanding; sudden trouble seeing in one or both eyes; sudden trouble walking, dizziness, loss of balance or coordination; sudden, severe or prolonged headache with no known cause; loss of consciousness or fainting with or without seizure.

Other signs of vascular occlusion can include: sudden pain, swelling and slight blue discoloration of an extremity; acute abdomen. Symptoms of MI can include: pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest, arm, or below the breastbone; discomfort radiating to the back, jaw, throat, arm, stomach; fullness, indigestion or choking feeling; sweating, nausea, vomiting or dizziness; extreme weakness, anxiety, or shortness of breath; rapid or irregular heartbeats.

Arterial thromboembolic events may be life-threatening or may have a fatal outcome. The potential for an increased synergistic risk of thrombosis should be considered in women who possess a combination of risk factors or exhibit a greater severity of an individual risk factor. This increased risk may be greater than a simple cumulative risk of the factors.

See Contraindications. If a hereditary predisposition is known or suspected, the woman should be referred to a specialist for advice before deciding about any COC use; prolonged immobilization, major surgery, any surgery to the legs, or major trauma.

In these situations it is advisable to discontinue COC use in the case of elective surgery at least four weeks in advance and not to resume until two weeks after complete remobilization; smoking with heavier smoking and increasing age the risk further increases, especially in women over 35 years of age ; dyslipoproteinemia; hypertension; migraine; valvular heart disease; atrial fibrillation.

There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in venous thromboembolism. Other medical conditions which have been associated with adverse circulatory events include diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel disease Crohn's disease or ulcerative colitis and sickle cell disease.

Biochemical factors that may be indicative of hereditary or acquired predisposition for venous or arterial thrombosis include Activated Protein C APC resistance, hyperhomocysteinemia, antithrombin-III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies anticardiolipin antibodies, lupus anticoagulant.

Tumors: The most important risk factor for cervical cancer is persistent HPV infection. Some epidemiological studies have indicated that long-term use of COCs may further contribute to this increased risk but there continues to be controversy about the extent to which this finding is attributable to confounding effects, e.

The excess risk gradually disappears during the course of the 10 years after cessation of COC use. Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer.

These studies do not provide evidence for causation. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. The breast cancers diagnosed in ever-users tend to be less advanced clinically than the cancers diagnosed in never-users. In rare cases, benign liver tumors, and even more rarely, malignant liver tumors have been reported in users of COCs. In isolated cases, these tumors have led to life-threatening intra-abdominal hemorrhages.

A liver tumor should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal hemorrhage occur in women taking COCs. Malignancies may be life-threatening or may have a fatal outcome.

Other conditions: Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs. Although small increases in blood pressure have been reported in many women taking COCs, clinically relevant increases are rare. However, if a sustained clinically significant hypertension develops during the use of a COC then it is prudent for the physician to withdraw the COC and treat the hypertension.

The aim of treatment with Diane 35 is to block the peripheral action of male hormones commonly present in the female body. When androgen activity is increased in women, conditions such as acne, seborrhea and hirsutism and female pattern baldness can result. These conditions are known as symptoms of androgenization. Cyproterone acetate inhibits the influence of androgens, and reduces the activity of the sebaceous gland which plays an important role in the development of acne and seborrhea.

Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects.

Do not be alarmed by the following lists of side effects. You may not experience any of them. The following list includes the more common side effects of Diane ED. These are usually mild and lessen with time. If you notice any of the following side effects and they worry you, tell your doctor or pharmacist:.

The following list includes very serious but rare side effects. You may need urgent medical attention or hospitalisation. If you experience any of the following, tell your doctor immediately, or go to the Emergency Department at your nearest hospital:. Blood clots may block blood vessels in your body. This type of blood clot is also called thrombosis.

Blood clots sometimes occur in the deep veins of the legs. If a blood clot breaks away from the veins where it has formed, it may reach and block the blood vessels of the lungs, causing pulmonary embolism. Blood clots can also occur in the blood vessels of the heart causing a heart attack or the brain causing a stroke. They can also happen during pregnancy.

The risk of having blood clots is higher in Diane ED users than in non users, but not as high as during pregnancy. The risk of a blood clot is highest during the first year of taking Diane ED for the first time, or after having a break from Diane ED for 4 weeks or more. If you notice possible signs of a blood clots, stop taking Diane ED and consult your doctor immediately. To prevent pregnancy, you must also use additional barrier contraceptive precautions e.

If you are concerned about an increased risk of blood clots while on Diane ED, speak to your doctor. Diane ED contains a progestogen and an oestrogen hormone, and therefore works similarly to the combined oral contraceptive birth control pill, the Pill. Breast cancer has been diagnosed slightly more often in women who take the Pill than in women of the same age who do not take the Pill.

This slight increase in the numbers of breast cancer diagnoses gradually disappears during the course of the 10 years after women stop taking the Pill. It is not known whether the difference is caused by the Pill. It may be that these women were examined more often, so that the breast cancer was noticed earlier. It is important that you check your breasts regularly and contact your doctor if you feel any lumps.

In rare cases benign liver tumours and, even more rarely, malignant liver tumours have been reported in users of the Pill. These tumours may lead to internal bleeding. Cervical cancer has been reported to occur more often in women who have been taking the Pill for a long time. This finding may not be caused by the Pill, but may be related to sexual behaviour and other factors. Keep your tablets in the blister pack until it is time to take them. If you take the tablets out of the pack they may not keep well.

Do not store your tablets or any other medicine in the bathroom, near a sink, or on a window-sill. Do not leave medication in the car. Heat and damp can destroy some medicines. Keep Diane ED where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines. If your doctor tells you to stop taking this medicine or the expiry date has passed, ask your pharmacist what to do with any medicine that is left over. Diane ED comes in a box containing either 1 or 3 blister packs.

Each blister pack contains 21 beige active tablets and 7 white inactive tablets. Tablets do not contain gluten. Tablets also do not contain tartrazine or any other azo dyes.

Skip to content. Keep this leaflet with the medicine. You may need to read it again. Tofu and Vegetable Curry Mains November 10, ,. Feel fit and fabulous this Christmas Christmas November 9, ,. Norman Swan Mental Health November 7, ,. Reuben Dip Dips November 6, ,. Next article Somac Heartburn Relief Tablets.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits.

However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept All. Manage consent. Close Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website.

These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience. Necessary Necessary. Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. The cookie is used to store the user consent for the cookies in the category "Analytics".

The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is used to store the user consent for the cookies in the category "Other. The cookie is used to store the user consent for the cookies in the category "Performance".

It does not store any personal data. Functional Functional. Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features. Performance Performance.